- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
26 October: The company who manufactured the convalescent plasma used in the study, Lilly, has released a statement regarding the end of the trial. While this ACTIV-3 clinical trial showed no benefit of bamlanivimab (the convalescent plasma treatment also known at LY-CoV555) for patients hospitalised with COVID-19, other studies using banlamivimab are continuing.
This includes ACTIV-2 for patients with mild-moderate disease, BLAZE-1 for people not hospitalised and BLAZE-2 for residents as well as staff in long-term care facilities. They state “we remain confident based on data from Lilly’s BLAZE-1 study that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
13 October: Media are reporting the manufacturer Eli Lilly, has paused its trial of a monoclonal antibody treatment for COVID-19. A spokesperson confirmed the pause stating, “Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.” The details regarding the safety concerns are as yet unknown. No information was available from the manufacturer’s site at the time of writing. Further information about the ACTIV-3 trial can be found here.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
